The FDA's Peptide Crackdown: A Complete Timeline
Timeline of FDA enforcement actions against peptide vendors from 2023-2026: warning letters, criminal cases, and regulatory changes.
Evidence-based analysis, vendor accountability, and honest guidance in a market flooded with marketing claims.
Timeline of FDA enforcement actions against peptide vendors from 2023-2026: warning letters, criminal cases, and regulatory changes.
Analysis of independent testing data revealing alarming quality failures in grey-market peptides. What Finnrick, Janoshik, and other labs have found.
Independent deep dive into Infiniwell's SNAC-enhanced BPC-157 products. We examine the technology claims, the missing studies, and what consumers should know.
Analysis of Pentadeca Arginate (PDA) claims: the patent, the chemistry, and the missing evidence behind '99% bioavailability' marketing.
How semaglutide went from pharmaceutical breakthrough to public health crisis. The compounding controversy, counterfeit risks, and what consumers need to know.
Critical analysis of TB-500 vs. Thymosin Beta-4. The research uses one molecule; the market sells another. We examine what the evidence actually supports.
An evidence-based analysis of oral BPC-157 bioavailability claims. We examine what the research actually shows versus what vendors tell you.
Analysis of the FDA's September 2025 enforcement wave: 50+ warning letters to peptide and GLP-1 compounders in a single month.
Learn to evaluate peptide COAs: what each test means, red flags for fake documentation, and which labs are considered credible.